Connect with us

Tech

Synex founder, once detained at the border with a 80-pound magnet, is building portable MRIs to test glucose

Back in 2019, Synex Medical founder Ben Nashman spent the night detained by US customs. Nashman tried to explain he was simply transporting materials from Buffalo to Toronto for his homemade MRI. Customs, however, took issue with the label on the package: “nuclear magnetic resonance.” 

Nashman spent hours in a bright waiting room before he finally convinced them that he was really just a run-of-the-mill 18-year-old scientist with an obsession with MRI technology. They let him take his roughly 80-pound magnet and he zoomed back to Toronto. “I got back at like 3 or 4 am and got a few hours of sleep before classes,” he said. 

Nashman, now 24, might have landed himself on a list of suspicious individuals, but he insists it was worth it: that one very long night was part of his years-long journey to build a portable MRI capable of testing glucose and other important molecules without the need to extract blood. Today, the company is one step closer to that goal, announcing a $21.8 million Series A fundraise, with investors like Accomplice, Radical Ventures, Fundomo and Khosla Ventures. It brings the company’s total haul up to over $36 million, with includes seed funding from Sam Altman. 

Right now, Synex’s prototype is the size of a toaster, although Nashman hopes to one day have it fit in your palm. It works by first using MRI to create a 3D image of the finger to find the best spot to test. It then uses something called magnetic resonance spectroscopy to send radio pulses that “excite the different molecules,” Nashman said. The machine then takes the signals from all the molecules and filters for a specific one. Synex will start with glucose testing, but will eventually track things like amino acids, lactate and ketones.  

The company introduced me to Diane Morency, a woman based in Massachusetts who has suffered from Type 2 diabetes for years. “I’ve got holes in my fingers,” she told me, adding she can no longer play her ukulele because of the pain. “It would be a godsend to not have to prick my [fingers] anymore.” 

But there’s a reason non-invasive glucose testing hasn’t been commercialized: it’s difficult to track glucose accurately without drawing blood, and it’s even harder to make the device portable or affordable. “We believed that was going to be an absolute moonshot,” said Jun Jeon, an investor at Khosla Ventures focusing on healthcare. 

Jeon has yet to try Nashman’s prototype but said that, if Nashman can deliver on his promises, then “this was a bet worth taking.” 

An obsession with longevity

Nashman was always curious about living forever. 

When he was about 16, he walked into his vet’s office armed with printed-out scientific studies. He had determined that his dog should be put on the immunosuppressive drug rapamycin, a drug controversially heralded by longevity enthusiasts. The vet had no idea what Nashman was talking about. “He was just like, ‘this is just way too experimental for me,’” Nashman recalled. 

The vet’s refusal didn’t deter him. “Later, I got my parents on it and I got on it,” he laughed. “Honestly, I think everything should be on it.” 

It was the first of several longevity self-experiments. Nashman briefly took diabetes drug arcarbos, forked over thousands for a Prenuvo full body scan, and, like so many in Silicon Valley before him, got his hands on a continuous glucose monitor. His health obsession coincided with a fascination with physics — particularly the “elegant” science behind MRIs, and how much they could reveal about the human body. 

By 17, he had ordered materials online to make a makeshift MRI in his bedroom (it was “really crap,” he said). By 18, he had held an internship working on brain imaging at the Mount Sinai Hospital in Toronto and enrolled at the University of Toronto for engineering science. “I think I have the record for most MRIs ever, probably,” he said. “I’ve probably scanned my finger honestly 1000s of times at this point.” 

He realized that MRI technology could be the ultimate longevity hack, giving him more information about his body than an Oura Ring or Whoop ever could. He first sold his dreams to Altman, whom he met in 2019, and then Peter Thiel, landing the Thiel Fellowship in 2021. 

Nashman may have Silicon Valley’s overlords on his side, but he’s still entering a very crowded space with well-capitalized competition. Startups like Know Labs and Berlin-based DiaMonTech are both making their own non-invasive products. Apple has reportedly been quietly working on a non-invasive glucose monitor, and Google too once tried to make its own glucose monitoring contact lens before pausing the project in 2018

Synex Medical faces an uphill battle from here. The company will have to undergo rigorous clinical trials to prove to the FDA that its machine can accurately isolate glucose molecules. There’s also the lingering question of whether Nashman can really get technology to a portable size. If not, “It wouldn’t be too useful,” Morency said. “It would do us no good outside of the house.” 

But let’s say Nashman nails all of that. Let’s say Synex soars through its FDA-approved trials and successfully shrinks its current metal toaster down to something that fits in your palm. It will still debut in a healthcare industry that has long struggled to make new technology affordable, according to Khosla investor Jeon. “There’s not a lot of good infrastructure and reimbursement that will allow for all patients to have access to the technology,” Jeon said. 

For Nashman, the chance for a longer life is worth dedicating his own life to. “I want to know exactly what my body needs. I want to know what my parents need,” he said. “A technology like this is just needed to usher in that age of predictive medicine.” 

source

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Tech

Can an Apple lawsuit derail OpenAI’s hardware plans?

Apple recently filed a trade secrets lawsuit against OpenAI, accusing the AI company of a pattern of misconduct aimed at getting current and former Apple employees to share confidential information. (In response, OpenAI said it is “not aware of any evidence that this complaint has merit.”)

On the latest episode of TechCrunch’s Equity podcast, Kirsten Korosec, Sean O’Kane, and I debated whether this lawsuit will cast a shadow over OpenAI’s much-discussed plans to get into the hardware business (starting with a mobile smart speaker) and go public.

“Even setting aside whether or not the court grants any kind of injunctive relief or any kind of restraining order over what OpenAI is doing, it just naturally can lead to that sort of situation where it’s going to cause some delays in what OpenAI is working on,” Sean suggested. “Which I’m sure was probably part of the reasoning behind Apple doing this. They don’t do this stuff willy nilly.”

With all those plans on the line, will OpenAI try to settle this as quickly as possible, or did it learn from its recent courtroom victory against Elon Musk that it can endure the cost and embarrassment of a trial? Kirsten, at least, predicts the latter.

Keep reading for a preview of our conversation, edited for length and clarity.

Kirsten: Sean, how do you feel about Sam Altman listening to you with a little device maybe in your pocket?

Sean: I’m good. Maybe that’s predictable, but I’m good. No thanks.

We’ll get into it, I’m sure, but this is allegedly the first product that OpenAI has been working on in its hardware division with Jony Ive and company. They’ve been really coy ever since that weird video they put out last year of them sitting at that coffee shop or bar in San Francisco and sort of talking very vaguely about hardware and legacy devices, meaning laptops and phones. And so if this is the direction they’re headed in, all power to people who want to have somebody like that always listening to them. This is not going to be for me.

Anthony: Part of what we have to remember about those kinds of devices is also that, depending on how mobile it is, it’s not just listening to you, it’s listening to the people around you. I might be fine with it — I’m not fine with it, but let’s say I was — but then if we met up in-person at Disrupt, then suddenly it might be listening to all of us. 

There are all kinds of social norms that are going to have to be renegotiated if these things become widespread. I think we should make fun of and criticize people who record other people without consent.

Kirsten: Well, I bring up the device that has been speculated about for a really long time, and we’ll see what it really ends up being once it’s officially introduced, but it’s important in the context of this lawsuit that Apple filed last Friday. 

It was the biggest news of the week, certainly, and this is a trade secret lawsuit. It has some pretty wild allegations and we should very much emphasize these are allegations that have been filed in a complaint by Apple. But what it is accusing OpenAI of is a pattern of misconduct at the highest levels, specifically directed towards OpenAI employees who used to work at Apple. And in fact they’ve named the chief hardware officer Tang Tan in this lawsuit.

This is all important because Apple is accusing OpenAI of essentially stealing their trade secrets, but in the context of that, this could be then used for a competing hardware product. I’m wondering if maybe we don’t get into whether this lawsuit has merits, because we haven’t gone through full discovery, but what are your initial impressions of the lawsuit aside from the fact that wow, this is going to be entertaining?

Sean: Two things. One, this is a pretty big risk potentially to whatever it is OpenAI is working on. Even setting aside whether or not the court grants any kind of injunctive relief or any kind of restraining order over what OpenAI is doing, it just naturally can lead to that sort of situation where it’s going to cause some delays in what OpenAI is working on, which I’m sure was probably part of the reasoning behind Apple doing this. They don’t do this stuff willy nilly.

The other is that we think that OpenAI is — we know that they’ve filed confidentially for an IPO. We think it might happen as early as the end of this year, or early next year, if you believe Sam Altman’s cautious language around the IPO. And this just raises a whole bunch of questions around that because, on the one hand, we think their business right now is probably overwhelmingly the software; they’re not really factoring in any hardware business into that picture at the moment.

They’re about to go to the markets and they’re going to be pitching bankers and investors on where they think their addressable market should be, and if they have a big amount of that pegged to a potential hardware division and hardware products, this could be a huge risk to that and changes a lot of the calculus of sort of how the IPO gets priced. So that’s where my head’s at.

Anthony: One [allegation] that I assume that Apple must have pretty solid numbers on is, they said more than 400 Apple employees now work at OpenAI. Granted, both of them are very large companies with many thousands or tens of thousands of employees. So as a percentage, it’s not necessarily huge. But that seems like a lot of people and a pretty serious talent drain. 

And the other thing I’m wondering is related to Sean’s point. With the context of the potential IPO, how much damage did OpenAI ultimately take from a marketing and brand perspective from the trial it already went through? That it seemed to basically win, but there was a lot of not-terrible-but-kind-of-embarrassing dirty laundry that came out in the testimony. To what extent are they just like, “We do not want to go through that again”? Or did they take the lesson of, “Hey, we went through it and we survived and we’ll be okay if we have to do another trial with Apple”?

Kirsten: I fully predict the latter, by the way.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

source

Continue Reading

Tech

What to watch for after Jensen Huang’s Japan visit

Nvidia’s chief Jensen Huang spent two days — July 15 and 16 — in Tokyo, courting Japan’s industrial and chip-supply elite, weeks after a keynote in Taiwan, and months after a visit to South Korea. He left with deals spanning Japan’s entire tech ecosystem: a national AI factory, partnerships with the country’s leading robotics companies, and agreements with the chip-material suppliers powering Nvidia’s next generation of AI chips. His message was clear. Nvidia is targeting Japan’s factory floor, and many of the country’s biggest manufacturers are joining in. AI’s next chapter, Huang said, belongs to factory floors, robots, and machines, and he wants Japan to build it.

Thirty years ago, a $5 million Sega investment helped keep a near-bankrupt Nvidia afloat; today, Nvidia and Japan’s industrial giants need each other again — this time to build the physical-AI era, starting with these three projects:

Noetra — Japan’s sovereign-AI play. The country doesn’t want to run its factories and robots on American or Chinese AI. So, the government pulled together roughly 44 domestic firms, with SoftBank, Sony, NEC, and Honda at the core, to build its own AI for robots, vehicles, and factory floors. Tokyo is committing up to 1 trillion yen ($6.2 billion) over five years, a bet on homegrown “physical AI,”  foundation models built to run machines. Japan wants to own the software brain. The hardware to build it, though, still comes from Nvidia. The U.S. chip giant is building “a Vera Rubin AI factory,” a massive data center packed with its next-generation chips, expected to launch in 2028, with 13,750 Vera CPUs and 27,500 Rubin GPUs, delivering 140 megawatts. Noetra will oversee the effort, with plans to build the data center. Noetra’s plan runs in three stages: a reasoning model heavy on Japanese-language skills starting in fiscal 2026; an omni-modal version handling text, images, video, and audio by 2028; and “Real-world Native AI” built to run robots by 2030, released to outside Noetra developers in phases.

The robotics coalition  — Japan’s industrial giants line up behind Cosmos. Nvidia is targeting Japan’s factory floor, and many of the country’s top robotics and manufacturing players are signing on. Fanuc, Yaskawa, Kawasaki Heavy, Fujitsu, Hitachi, NEC, Sony, SoftBank, Kubota, and robotics group AIRoA say they plan to build on Nvidia’s Cosmos models, an open-model effort Nvidia started in May with a handful of global AI labs. In Tokyo, Nvidia gave them a reason to commit, unveiling Cosmos 3 Edge, a version of the model that runs on its Jetson Thor chips inside the machines themselves. Some are already testing a shared control system; others, like Honda R&D and Omron, are building on the tools now. “The next frontier of AI is in the physical world, and this is a once-in-a-generation opportunity for Japan,” Huang said in the company’s statement. “Japan invented modern manufacturing. Now, it has the opportunity to reinvent it for the age of intelligent industries.”

Toyota — cars and physical AI. Toyota uses Nvidia chips across much of its stack. It committed its next-generation vehicles to Nvidia’s Drive platform at CES in January 2025; the newer work extends Nvidia into its manufacturing, where simulations are used to design production lines, into the software that runs its vehicles, and into systems that read road traffic. Toyota’s cars will run advanced driver assistance, which steers and brakes but still requires a driver, a more conservative approach than Waymo and Tesla, which are developing systems that rely less on a human driver.

Huang’s visit put physical AI at the center of Japan’s industrial strategy, and Tokyo is spending to back it. Facing a shrinking workforce, Japan wants 10 million AI-equipped robots across 18 sectors by 2040, backed by $65 billion in public and private physical-AI investment.  

The longer game is bigger. Japan’s AI Robotics Strategy, released in March, aims to capture more than 30% of the global AI robotics market by 2040, a market Tokyo values at roughly ¥20 trillion, or about $133 billion. METI is funding a domestic foundation model to run the machines, and Noetra’s Nvidia-powered factory is where models of that scale, into the trillions of parameters, would be trained.

Underneath the industrial case is a sovereign one. As the U.S. and China pull ahead in large-scale AI, Tokyo wants its own data, its own compute, and less dependence on infrastructure it doesn’t control. Huang appeared on July 16 alongside trade minister Ryosei Akazawa at the government’s physical-AI launch, with Prime Minister Sanae Takaichi joining by video. The Takaichi administration has made AI and semiconductors the centerpiece of a growth plan chasing ¥370 trillion ($2.3 trillion) in public and private investment by 2040. Noetra’s factory — which Nvidia bills as “the world’s first national AI infrastructure” — is the clearest bet yet. Japan’s push for independence, at least for now, rests on American chips.

In two days, Huang sat across from nearly every name that matters in Japanese tech — the CEOs of Toyota, Fanuc, Yaskawa, Fujitsu, and Kawasaki over lunch, and dozens of supply-chain chiefs over skewers and whisky in a Kanda izakaya.

It’s the same playbook he ran weeks earlier — a homecoming keynote in Taiwan, fried chicken, and a 50,000-GPU deal in Seoul last fall. This time, it was Tokyo’s turn, with the robots, the supply chain, and the chips underneath.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

source

Continue Reading

Tech

Netflix paid $587M for Ben Affleck’s AI filmmaking startup

In a new regulatory filing, Netflix revealed that it paid $587 million in cash for InterPositive, a startup co-founded by actor and director Ben Affleck.

The streaming company announced the acquisition in March, with a statement from Affleck saying he wanted to “protect the power of human creativity.” According to Affleck, InterPublic’s AI tools help filmmakers improve their footage in post-production, particularly when it comes to making up for “real-world production challenges such as missing shots, background replacements or incorrect lighting.”

At the time, Netflix announced that the entire InterPositive team would be joining the company, with Affleck joining as a senior advisor, but it didn’t disclose the financial terms of the deal. A subsequent report in Bloomberg suggested that the deal could be worth up to $600 million.

In its most recent earnings report, Netflix said that around 300 of its titles have already used generative AI.

source

Continue Reading